3 stories tagged cancer-vaccine, newest first.
136 points by _Microft | 25 comments
Ars Technica article reporting Phase 3 results showing Moderna and Merck's personalized mRNA melanoma vaccine with Keytruda cut recurrence or death risk by 42%.
498 points by heydenberk | 231 comments
X post by Moderna co-founder Noubar Afeyan announcing positive Phase 3 results for intismeran autogene, an individualized mRNA neoantigen therapy for melanoma with Keytruda.
324 points by nateb2022 | 162 comments
Freethink article reporting that Moderna's personalized mRNA cancer vaccine significantly boosts a standard melanoma treatment's effectiveness.